Clinical Trials Logo

Clinical Trial Summary

Metoclopramide (Reglan) is a common agent used for relief of headaches in the emergency department (ED).In this study the investigators seek to explore another option for treatment of headaches in the ED, one that may be more efficacious and efficient. Haloperidol (Haldol), a butyrophenone class of medication, is thought to act by affecting the dopamine 2 receptor in the brain.

By exploring haloperidol as an option for treatment, the investigators hope to discover a more efficient and effective medication for the treatment of non-traumatic headaches, thereby decreasing a patient's length of stay in the department and decreasing the rate of return visits for continued discomfort from the same headache. This study could lead to the increased usage of haloperidol as a first line agent in the treatment of prolonged headaches presenting to the ED.


Clinical Trial Description

At this time, choice of medications for the treatment of headaches in the ED is still based on personal and patient preferences because no properly constructed trials have been carried out that would allow identification of a superior agent. Metoclopramide (Reglan) is a common agent used for relief of headaches in the ED. Uncontrolled studies have shown successful relief of migraine with metoclopramide of 75%. Further studies have reported success rate of 67% with IV metoclopramide. In this study the investigators seek to explore another option for treatment of headaches in the ED, one that may be more efficacious and efficient. Haloperidol (Haldol), a butyrophenone class of medication, is thought to act by affecting the dopamine 2 receptor in the brain. These receptors are relatively abundant in the brainstem nuclei and sympathetic ganglia and nerves, through which they may regulate autonomic visceral, gastrointestinal, and hemodynamic responses frequently associated with migraine. One study, demonstrated that 4 out of 5 patients felt significant relief in pain intensity with the use of haloperidol, even when other medications had failed. Relapses were rare, and several patients reported that haloperidol interrupted the prolonged, intractable migraine spiral they had suffered for days. Furthermore, a case series of six cases of migraine treated with 5mg of haloperidol IV after a 500 to 1000ml bolus of IV fluids reported complete or substantial relief within 25 to 65 minutes and side effects were reported as minimal.

The investigators hypothesize that Haloperidol is more efficacious than metoclopramide in the treatment of an acute headache or migraine in the ED in regard to a self-reported pain rating scale (Numeric Pain Intensity Scale), need for additional medication, emergency department return rates, and resolution of symptoms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02972502
Study type Interventional
Source OhioHealth
Contact
Status Terminated
Phase Phase 4
Start date February 2014
Completion date April 24, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT05503082 - Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies Phase 4
Completed NCT04905654 - Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura N/A
Completed NCT04111484 - Adrenomedullin Effect on Migraine Without Patients N/A
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT03337620 - Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine Phase 3
Completed NCT02259387 - Adolescents With Migraine: What's Stress Got To Do With It?
Completed NCT05658185 - Migraine Difficult to Treat: the Importance of Psychological Care in the Chronic Patient N/A
Completed NCT05001399 - Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain N/A
Completed NCT03490500 - Using the S100B Protein for Emergency Headache Management Care (S100)
Completed NCT03075020 - Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura. N/A
Recruiting NCT03472092 - Mind and Body Approaches to Pain Reduction in Youth With Migraine Phase 2
Enrolling by invitation NCT04976985 - Osteopathic Manipulative Treatment and Migraine Headaches N/A
Active, not recruiting NCT04372264 - Intravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache Phase 4
Recruiting NCT04623203 - The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
Completed NCT04577443 - The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties. N/A
Completed NCT03560024 - The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers N/A
Completed NCT03228355 - Headache Inducing Effect of Cromakalim in Migraine Patients N/A
Completed NCT02438553 - Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain N/A
Recruiting NCT03577548 - Influence of Main Psychological and Social Factors on Primary Headaches
Recruiting NCT04715685 - Mind Body Balance for Pediatric Migraine N/A